Understanding Pathophysiology and Copper Transport in Wilson Disease

In 'Understanding Pathophysiology and Copper Transport in Wilson Disease,' our experts delve into the underlying biological drivers of this autosomal recessive metabolic disorder. Dr. Peter Hedera provides a technical overview of the ATP7B gene, a critical copper transporter located primarily in the liver, kidneys, and brain. Under normal physiological conditions, this protein facilitates the transfer of copper to ceruloplasmin for transport and manages the excretion of excess dietary copper into the bile. However, a loss of function in ATP7B leads to chronic copper overload, causing a shift toward what is known as non-ceruloplasmin copper or biologically active copper.

The panel discusses how this "free" copper becomes highly toxic when it exceeds the body's buffering capacity. Historically referred to as hepatolenticular degeneration, the disease specifically targets the liver and the basal ganglia of the brain due to the high metabolic activity in these areas. Dr. Hedera explains that while patients are born with this genetic deficiency, clinical presentation typically peaks in the second and third decades of life, though rare cases appear much later.

The experts also explore the multi-system defects caused by abnormal copper metabolism. They highlight that the disruption of oxidative systems and subsequent mitochondrial dysfunction are primary drivers of cellular damage. This process leads to hepatic cell death and neurodegeneration, illustrating why copper, though an essential trace element, becomes a destructive force when regulation is broken. The episode concludes by emphasizing the importance of understanding these cellular pathways to better recognize the diverse clinical manifestations seen in practice.

Our next episode, 'Early Clinical Signs and the Evolution of Diagnosis in Wilson Disease,' further explores Wilson disease, highlighting the critical role of elevated liver enzymes as a primary clinical trigger for evaluation. The panelists discuss the emerging era of neonatal screening and the necessity of combining laboratory testing with clinical suspicion to identify this master masquerader.